Helicobacter Pylori Clinical Trial
Official title:
Effect of Helicobacter Pylori Eradication on the New Tumor Development After Endoscopic Resection of Gastric Tumors
The purpose of this study is to determine whether Helicobacter pylori eradication could reduce the new tumor development after endoscopic resection of gastric tumor.
The association between Helicobacter pylori infection and development of gastric cancer has
been established by epidemiologic studies. Conversely, eradication of H. pylori showed no
significant reduction of the incidence of gastric cancer in a large-scale, double-blind,
randomized controlled trial. Eradication of H. pylori to prevent cancer was only effective
in the subgroup without precancerous lesions (i,e, dysplasia, intestinal metaplasia, and
atrophy). In contrast, randomized prospective study in Japan showed that H. pylori
eradication after endoscopic resection of early gastric cancer significantly reduced
metachronous gastric cancer. To solve this conflicting issue is critical because gastric
cancer is the second leading cancer incidence worldwide, particularly Korea, Japan, and
China have highest cancer incidence, and its incidence might decrease by H. pylori
eradication treatment.
With respect to therapeutic modality, endoscopic resection for early gastric cancer is
currently the established treatment of choice in Korea and Japan because it has been proven
to be both minimally invasive and effective in the curative treatment of early gastric
cancer.
Endoscopic resection has also been performed in the gastric dysplasia because dysplasia has
to some extent malignant potential although firm evidence is lacking. In comparison with
surgical resection, endoscopic resection conserves remnant stomach. Accordingly, patients
treated with endoscopic resection have higher possibility for metachronous gastric cancer
than those treated with surgical resection.
So far, it has not yet been clearly established whether H pylori eradication for gastric
tumors (early gastric cancer and gastric dysplasia) could reduce metachronous cancer. We
performed randomized controlled, open-label trial on the effect of new cancer development
after H pylori eradication for gastric tumors.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02892409 -
TAK-438 Bismuth Drug Interaction Study
|
Phase 1 | |
| Completed |
NCT05073367 -
A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
|
||
| Completed |
NCT00596401 -
The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
|
||
| Not yet recruiting |
NCT04101708 -
A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients
|
Phase 4 | |
| Recruiting |
NCT04029415 -
The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
|
||
| Recruiting |
NCT04030715 -
The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study
|
N/A | |
| Recruiting |
NCT04029493 -
The Situation of Re-infection of Helicobacter Pylori After Successful Eradication
|
||
| Not yet recruiting |
NCT02933229 -
The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study
|
Phase 4 | |
| Not yet recruiting |
NCT02934048 -
Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection
|
Phase 4 | |
| Recruiting |
NCT05184491 -
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
|
Phase 4 | |
| Recruiting |
NCT05790525 -
Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy
|
Phase 4 | |
| Completed |
NCT05790512 -
Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
|
||
| Recruiting |
NCT05276557 -
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
|
Phase 3 | |
| Recruiting |
NCT03177629 -
H. Pylori Eradication for Moderate ITP
|
Phase 3 | |
| Recruiting |
NCT05053945 -
Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
|
||
| Recruiting |
NCT05449028 -
Helicobacter Pylori Eradication Therapy in Portugal
|
N/A | |
| Recruiting |
NCT00306280 -
Feasibility Study of Phototherapy System to Treat H Pylori
|
N/A | |
| Active, not recruiting |
NCT02675010 -
Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study
|
N/A | |
| Withdrawn |
NCT00467155 -
Helicobacter in The Gambia (Part 2)
|
N/A | |
| Completed |
NCT03716622 -
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication
|
Phase 4 |